List of Next-Gen Sequencing Companies in Massachusetts - 29

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Formerly called Bioline, now acquired by Meridian Bioscience, as part of Meridian Life Science business unit, was founded in 1992 and based in London, UK. Meridian Bioscience is a fully integrated company with two business units dedicated to diagnostics and life science. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Meridian Life Science unit,with large-scale manufacturing capabilities and over 3500 products, provides the most comprehensive portfolio of raw materials for the clinical development of any immunological or molecular test. Our molecular reagents are used by biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology to food and agriculture technology as well as forensic and environmental sciences, where life scientists have come to depend upon the outstanding quality and reliability of our reagents. We have developed and manufactured a portfolio of more than 300 reagents and kits, many of them proprietary, for molecular biology, cell analysis and nucleic acid and protein separation and purification. Meridian operates under an ISO 13485 quality system and is one of the world's few manufacturers of ultra-pure dNTPs, as well as a variety of enzymes and biochemicals.

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

Fluent BioSciences, an Illumina company, is a biotechnology company with a mission to accelerate the understanding of biology and disease through simple, cost effective and scalable solutions for every laboratory from research to the clinic. Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

FORMULATRIX® supplies innovative software and robotic automation solutions to the life science industry including the leading pharmaceutical companies and academic research institutions around the world. We collaborate with researchers to simplify scientific workflows such as sample preparation and analysis by designing solutions without boundaries and bringing novel cutting-edge technology into the laboratory. We are committed to researchers, their labs, and to the scientific discoveries that will improve the lives of generations to come.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines

Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders in many disciplines who make a difference globally. Founded in 1636, Harvard is the oldest institution of higher learning in the United States. The official flagship Harvard social media channels are maintained by Harvard Public Affairs and Communications and aim to provide access to the people, places, events, news and research at our Institution. We ask that all visitors to Harvard's digital spaces be civil to one another and to the site editors. Personal attacks, profanity, commercial solicitations, spam, misinformation or other inappropriate contributions are grounds for comment removal. We ask that you stay on topic when contributing to a discussion and refrain from duplicate posts. Hateful or discriminatory comments regarding race, ethnicity, religion, gender, disability, sexual orientation, or political beliefs will not be tolerated. The page administrators reserve the right to delete inappropriate or abusive comments and to permanently ban or block users from the Harvard social media accounts.

The Faculty of the Horae Gene Therapy Center is dedicated to developing therapeutic approaches for rare inherited disease for which there are no cures. They utilize state of the art technologies to correct the genetic mutations underlying the diseases. The Center focuses on AAT Deficiency, Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease), Canavan Disease, Cystic Fibrosis, Tay-Sachs & Sandoff diseases, Retinitis Pigmentosa, Huntington's disease, Hypercholesterimia, and Cardiac Arrhythmia.The Center operates under the umbrella of the Advanced Therapeutics Cluster (ATC) of UMass, whose mission is to apply knowledge flowing from the latest biomedical discoveries, develop new ways to treat diseases, and drive those therapies into clinical trials.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

MassBiologicsis a non-profit FDA-licensed manufacturer of vaccines. For over 100 years, MassBiologics has worked to improve public health through applied research, development and production of biologic products, including vaccines, plasma derivatives and more recently, monoclonal antibodies. MassBiologics currently manufactures Tetanus and Diptheria Toxoids, Adsorbed (Td) vaccine and distributes them nationwide.

Develops the LoopCap,™ a 4-step NGS workflow that removes the need for conventional library prep and generates a targeted, sequencer-ready library of molecules representing genomic regions of interest in a highly redundant manner.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

As the leader in Decision Medicine™, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won't stop until all of the cells' secrets are revealed.

Sage Science products are built on the idea that science is more robust and reliable when it is based on high-precision, automated, reproducible technology instead of manually intensive steps that introduce variability and error. We look at molecular biology workflows and identify high-value steps that can be significantly improved with accurate, automated solutions. Our products not only reduce hands-on time and boost throughput, but they also improve data quality and downstream results for life science and diagnostic labs. The Sage Science portfolio includes products to perform DNA or cDNA size selection: Pippin Prep for short-read NGS platforms and the BluePippin for short and long-read NGS platforms. The SageELF provides whole-sample fractionation of DNA for various applications. The SageHLS offers a new twist on DNA target enrichment. DNA is first extracted from cells directly on the platform. Then Cas9 endonuclease/guide RNA complexes are used to excise and collect large targets (entire genes or genomic regions, up to 500MB in length) from a genome. Large target enrichment, called CATCH (Cas9 assisted targeting of chromosomal segments) is used to elucidate difficult genomic structures such as pseudogenes, SVs, and repeat elements. Sage Science is privately funded. It is headquartered and manufactures at 500 Cummings Center in Beverly, MA, USA.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

seqWell was created to revolutionize NGS library prep to unlock the full potential of today’s DNA sequencing instruments. Our plexWell™ platform is a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. plexWell has wide-ranging impact on applications from synthetic biology, targeted sequencing and single-cell analysis to low and high depth sequencing of human, plant, animal and microbial genomes. In addition to plexWell, seqWell is also developing library prep methods for reagent-based approaches for long-molecule phasing and read linking. We invite you to learn more at https://seqwell.com

Syd Labs, a recombinant company based in Boston, Massachusetts, is dedicated to providing quality products and services for research and development in academy, industry, and government. We have always tried our best to let you, our valuable customers and partners, save money and work better. Syd Labs, Inc provides very comprehensive and competitive services for antibody services, from peptide synthesis, gene synthesis, protein expression, rabbit and mouse polyclonal antibody development, mouse, rat, and rabbit monoclonal antibody development, cloning variable regions of hybridoma cell lines, antibody humanization and engineering, stable cell line generation, ELISA assay development, and so on. The lowest prices are guaranteed. If you find any US company providing the same quality services with lower prices, we will return the difference to you.

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Thermagenix supplies high-quality reagents that measurably improve PCR fidelity and performance.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

The Tufts facility works to provide quick and convenient, high quality services to scientists from academia and industry around the world. Although the primary mission is support of the researchers at Tufts University, many of its users are from outside of Tufts. They provide the following services:DNA SynthesisDNA SequencingNext-gen SequencingPeptide SynthesisProtein SequencingMass Spectrometer Analysis

Universal Sequencing Technology focuses on innovative Long-Read DNA Sequencing solutions. Our Tell-Seq technology simply turns a 2nd generation DNA sequencer into a 3rd gen, Long-Read Sequencer. The affordable TELL-Seq WGS library prep kit is used in Metagenomics, de novo Assembly, Whole Genome Phasing, and Structural Variant identification. We provide the kit and the analysis pipeline and all you need are the samples and some common lab equipment. No need to buy expensive 3rd generation sequencers. No need to buy droplet making equipment. No need to follow overly complicated protocols. No longer limited by genome size. The Tell-Seq WGS Library Prep kit is affordable without the added expense of an instrument. The protocol takes only 3 hours to run and can be used for genomes ranging from 1 Mb to 5 Gb. Again, this is Long-Read Sequencing Made Simple.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, fueling innovation and creating insights that radically improve human health. Our goal is to use data to radically improve healthcare globally and create value through multiomics and insights. If you’re interested in learning more about Velsera, please follow us and visit our website at velsera.com! Looking for someone to get in touch with? Please email hello@velsera.com

At Veritas, we apply science and our global resources to bring genetic and genomic diagnostics to people to extend and significantly improve their lives. Our global portfolio includes preventive medicine, perinatal medicine, and genomic diagnostic services. In March 2022 Veritas announced that it was becoming part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York. In keeping with our responsibility as a leading biotechnology company, we collaborate with healthcare providers, governments, and local communities to support and expand access to genetic and genomic medicine reliably and affordably around the world.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.